Drew T. Dickinson

Drew T. Dickinson

Auto-generated profile, based on publicly available information

Drew T. Dickinson

Department of Pharmacy, Mayo Clinic , Phoenix, AZ

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2025 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
WYWei-Teng Yang
Wei-Teng Yang
JMJessica A Meisner
Jessica A Meisner
CMChristina Maguire
Christina Maguire
KDKelly E Dyer
Kelly E Dyer
RMRachel McFadden
Rachel McFadden
KDKathleen O Degnan
Kathleen O Degnan
Xylazine, an adulterant of unregulated opioid supplies, is increasingly prevalent in the United States and associated with distinctive wounds. Xylazine-associated wounds (XAWs) are primarily noted in the extremities and are not always associated with injection drug use. XAWs are often chronic and can become superinfected, posing a great challenge to clinical care. We share multidisciplinary guidance to care for persons with XAWs: (1) substance use disorder treatment and longitudinal multidisciplinary care including addiction medicine, wound care, infectious diseases, and surgery are imperative; (2) avoid aggressive debridement; (3) administer empirical antibiotics for methicillin-resistant Staphylococcus aureus (MRSA)– and group A Streptococcus (GAS)–infected wounds, specifically oral trimethoprim-sulfamethoxazole for MRSA and oral β-lactams for GAS; (4) administer intravenous daptomycin to reduce the discomfort and challenges associated with frequent phlebotomy for vancomycin therapeutic drug monitoring; and (5) create explicit contingency antibiotic plans with potential use of linezolid, tedizolid, or dalbavancin for patient-directed hospital discharge.

1 February 2022 in Currents in Pharmacy Teaching and Learning
Verified
Journal Article
Closed access
DDDrew Dickinson
Drew Dickinson

27 September 2019 in Infection Control & Hospital Epidemiology
Verified
Journal Article
Closed access
PDF file
DDDrew T. Dickinson
Drew T. Dickinson
SRSyma Rashid
Syma Rashid
AWAnastasiia Weiland
Anastasiia Weiland
TTThomas Tjoa
Thomas Tjoa
DKDiane S. Kim
Diane S. Kim
SHSusan S. Huang
Susan S. Huang
We performed systematic review on 40 paired hospital and nursing home charts from a clinical trial to evaluate the fidelity of transitions of care among those discharged on antibiotics. We found that 30% of transitions included an inappropriate change to the patient’s antibiotic plan of care.

11 September 2026 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
PCPatrick D Crowley
Patrick D Crowley
LSLeslie R Siegel
Leslie R Siegel
DDDrew T Dickinson
Drew T Dickinson
BLBrian D Lahr
Brian D Lahr
FWFrancis X Whalen
Francis X Whalen
DCDouglas W. William Challener
Douglas W. William Challener
Background: At hospice enrollment, patients are asked for preferences regarding antibiotic use. Limited evidence on how these medications impact survival makes it difficult for clinicians to offer clear guidance. To support decision making and antimicrobial stewardship, we assessed the association between antibiotic use and survival in outpatient hospice patients. Methods: The association between antibiotic use and survival was evaluated using a time-dependent Cox proportional hazards model, adjusted for age, sex, Charlson Comorbidity Index, and hospice-qualifying conditions (HQCs). The cohort included patients enrolled in a large health system's outpatient hospice program between 20 June 2017 and 1 January 2023. Results: Among 6169 patients with an HQC, 1233 received at least 1 antimicrobial prescription during the study period. The median time from hospice enrollment to first prescription was 16 days (interquartile range [IQR] 3–83). Antimicrobial prescribing patterns varied by HQC category. In time-dependent Cox models, antibiotic use was associated with increased hazard of death (adjusted hazard ratio [aHR] 1.47; 95% confidence interval [CI], 1.37–1.57).Stratified analyses showed the strongest association with increased mortality in patients with cancer HQCs (aHR 1.67; 95% CI, 1.50–1.87) and a survival benefit in those with infectious HQCs (aHR 0.60; 95% CI, .40–.89). Conclusions: Physicians, patients, and families often overestimate the benefits of antibiotics near the end of life. The observed increase in mortality shortly after antibiotic initiation suggests that symptoms prompting antibiotic use may reflect the dying process rather than treatable infection. Knowledge of the limited role of antibiotics in prolonging life in hospice settings may improve decision-making and enhance the quality of end-of-life care.

18 July 2025 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Verified
Journal Article
Closed access
DIDan Ilges
Dan Ilges
YFYakun Fu
Yakun Fu
DDDrew T. Dickinson
Drew T. Dickinson
JRJohn Robinson
John Robinson
LSLisa Speiser
Lisa Speiser
DNDavid P. Nicolau
David P. Nicolau

12 February 2025 in Antimicrobial Stewardship & Healthcare Epidemiology
Verified
Journal Article
Open access
PDF file
DDDrew T. Dickinson
Drew T. Dickinson
SSStephen Saw
Stephen Saw
LDLauren Dutcher
Lauren Dutcher
CMChristina Maguire
Christina Maguire
ATAdrienne Terico
Adrienne Terico
SPSonal Patel
Sonal Patel
Objective: Develop a Staphylococcus aureus wound antibiogram among patients who use fentanyl (PWUF) presenting with acute S. aureus skin and soft tissue infections (SSTIs) in Philadelphia, Pennsylvania. Design: Retrospective, multisite cohort study. Patients and Setting: Individuals presenting to emergency departments or admitted to inpatient units of four Penn Medicine hospitals with an acute S. aureus SSTI and illicit fentanyl use within the previous year. Methods: We described susceptibilities of S. aureus isolated from wound cultures among the PWUF cohort and compared these to the health system’s wound antibiogram. We compared frequency of in-hospital medication treatment for opioid use disorder among patients who left the hospital prior to vs after the availability of S. aureus susceptibilities. Results: Among 131 S. aureus isolates from 131 PWUF, 35/131 (26.7%) were susceptible to oxacillin, 73/121 (60.3%) were susceptible to clindamycin, 77/122 (63.1%) were susceptible to tetracycline, and 119/126 (94.4%) were susceptible to trimethoprim-sulfamethoxazole. PWUF displayed significantly reduced susceptibility to oxacillin and tetracycline compared to the health system’s outpatient wound S. aureus antibiogram. Compared to patients discharged prior to susceptibility availability, more patients discharged after the reporting of susceptibilities were administered buprenorphine or methadone in the hospital (82.0% vs 51.4%, P < 0.001). Conclusion: High nonsusceptibility to clindamycin and tetracycline suggests these agents should not be prescribed as empiric therapy for acute S. aureus SSTI in PWUF in Philadelphia. PWUF would benefit from joint management by infectious diseases and addiction medicine experts to ensure prescription of active therapy. Additional study is needed of PWUF in other regions.